A Balancing Act: Efflux/Influx in Mycobacterial Drug Resistance | Zendy

Gabriel Louw | Zendy; Robin M. Warren | Zendy; Nicolaas C. Gey van Pittius | Zendy; Christopher R. McEvoy | Zendy; Paul D. van Helden | Zendy; T. C. Victor | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Balancing Act: Efflux/Influx in Mycobacterial Drug Resistance

Author(s) -

Gabriel Louw,

Robin M. Warren,

Nicolaas C. Gey van Pittius,

Christopher R. McEvoy,

Paul D. van Helden,

T. C. Victor

Publication year - 2009

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01577-08

Subject(s) - efflux , drug resistance , drug , pharmacology , microbiology and biotechnology , medicine , biology , biochemistry

Since the discovery of the tubercle bacillus by Robert Koch in 1882 (110), a greater understanding of the dynamics and survival mechanisms of this pathogen has led to more ques- tions than answers. Despite stringent control strategies and many advances in our knowledge of the epidemiology of tu- berculosis (TB) and the biology of the causative agent Myco- bacterium tuberculosis, TB still remains one of the most common and deadly infectious diseases worldwide. The emer- gences of multidrug-resistant TB (MDR-TB) (with resistance to at least the first-line drugs isoniazid (INH) and rifampin (rifampicin) (RIF)) (39) and extensively drug-resistant TB (XDR-TB) (with additional resistance to a fluoroquinolone (FQ) and any one of the injectable drugs kanamycin (KAN), amikacin (AMI), and capreomycin (CAP)) (43, 67) are a major

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research